We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+35.97%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
+$343M
Cap. Flow
+$210M
Cap. Flow %
19.51%
Top 10 Hldgs %
30.46%
Holding
99
New
30
Increased
28
Reduced
17
Closed
19

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$29M
2
INSM icon
Insmed
INSM
+$26.6M
3
HUM icon
Humana
HUM
+$22.7M
4
CYTK icon
Cytokinetics
CYTK
+$19.3M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$15.7M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$19.9M
2
TFX icon
Teleflex
TFX
+$17.5M
3
NTRA icon
Natera
NTRA
+$13.2M
4
ZBH icon
Zimmer Biomet
ZBH
+$12.2M
5
LLY icon
Eli Lilly
LLY
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERA icon
26
Vera Therapeutics
VERA
$2.17B
$15.5M 1.44%
+360,000
New +$12.8M
CRNX icon
27
Crinetics Pharmaceuticals
CRNX
$8.95B
$15.2M 1.41%
325,000
+125,000
+63% +$4.89M
ICLR icon
28
Icon
ICLR
$12.8B
$15.1M 1.4%
45,000
+10,000
+29% +$2.95M
CRSP icon
29
CRISPR Therapeutics
CRSP
$5.23B
$15M 1.39%
+220,000
New +$15.7M
CI icon
30
Cigna
CI
$72.4B
$14.5M 1.35%
+40,000
New +$13.2M
KRYS icon
31
Krystal Biotech
KRYS
$9.68B
$14.2M 1.32%
80,000
-5,000
-6% -$695K
DXCM icon
32
DexCom
DXCM
$33.8B
$13.9M 1.29%
100,000
-25,000
-20% -$3.14M
INSM icon
33
CALL
Insmed
INSM
$29B
$13.6M 1.26%
+500,000
New +$14M
RVMD icon
34
Revolution Medicines
RVMD
$44.1B
$13.5M 1.26%
420,000
+220,000
+110% +$6.52M
SWAV
35
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$13M 1.21%
+40,000
New +$9.82M
AVTR icon
36
Avantor
AVTR
$9.31B
$12.8M 1.19%
500,000
+300,000
+150% +$7.14M
COR icon
37
Cencora
COR
$63.7B
$12.1M 1.13%
50,000
-20,000
-29% -$4.6M
TNYA icon
38
Tenaya Therapeutics
TNYA
$168M
$11.8M 1.09%
+2,250,000
New +$10.8M
COO icon
39
Cooper Companies
COO
$15B
$11.2M 1.04%
110,000
-30,000
-21% -$2.9M
MLTX icon
40
MoonLake Immunotherapeutics
MLTX
$1.41B
$11.1M 1.03%
220,000
– –
EXAS
41
CALL
DELISTED
Exact Sciences
EXAS
$10.4M 0.96%
+150,000
New +$9.49M
MLTX icon
42
CALL
MoonLake Immunotherapeutics
MLTX
$1.41B
$10M 0.93%
+200,000
New +$10.8M
SANA icon
43
Sana Biotechnology
SANA
$1.05B
$9.8M 0.91%
+980,000
New +$7.34M
NARI
44
DELISTED
Inari Medical, Inc. Common Stock
NARI
$9.6M 0.89%
200,000
+100,000
+100% +$5.34M
LLY icon
45
Eli Lilly
LLY
$1.08T
$9.34M 0.87%
12,000
-16,000
-57% -$11.4M
RGEN icon
46
Repligen
RGEN
$9.3B
$9.2M 0.85%
50,000
-5,000
-9% -$952K
ALPN
47
DELISTED
Alpine Immune Sciences Inc
ALPN
$9.12M 0.85%
+230,000
New +$6.79M
ELAN icon
48
Elanco Animal Health
ELAN
$11.4B
$8.95M 0.83%
550,000
+50,000
+10% +$782K
APLS
49
DELISTED
Apellis Pharmaceuticals
APLS
$8.82M 0.82%
+150,000
New +$9.56M
ITCI
50
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.65M 0.8%
125,000
-50,000
-29% -$3.44M
1
2
3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Integral Health Asset Management held 99 positions worth $1.08B, up 47% from $734M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Integral Health Asset Management deployed $210M of net new capital in Q1 2024, opening 30 new positions and adding to 28 existing holdings. Its largest new stake was Merck: 235,000 shares worth $31M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Natera, an estimated $13.2M trimmed.

  • Integral Health Asset Management's largest Q1 2024 buy was Merck: 235,000 shares worth $31M.
  • Integral Health Asset Management added most to Insmed in Q1 2024, an estimated $26.6M increase.
  • Integral Health Asset Management's biggest Q1 2024 reduction was Natera, cutting an estimated $13.2M.
  • Integral Health Asset Management fully exited Sanofi in Q1 2024, selling an estimated $19.9M.
  • Integral Health Asset Management's ten largest holdings make up 30% of its $1.08B portfolio in Q1 2024.
  • Integral Health Asset Management opened 30 new positions and closed 19 in Q1 2024.
  • Integral Health Asset Management's portfolio value rose 47% quarter-over-quarter to $1.08B.

Based on Integral Health Asset Management's 13F filing for Q1 2024, filed 15 May 2024.